ArticleGenetic vaccines and therapy2007
Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene.
Article in Genetic vaccines and therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Inhibition of autophagy promotes human RSV NS1-induced inflammation and apoptosisExperimental and therapeutic medicine · 2021Article
- Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.Chemico-biological interactions · 2019Review
- Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections.Journal of clinical medicine · 2018Review
- Inhibition of Respiratory Syncytial Virus Replication by Simultaneous Targeting of mRNA and Genomic RNA Using Dual-Targeting siRNAs.Molecular biotechnology · 2016Article
- Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.The Journal of general virology · 2015Article
- cRGD grafted siRNA nano-constructs for chemosensitization of gemcitabine hydrochloride in lung cancer treatment.Pharmaceutical research · 2015Article
- Cross-protective effect of antisense oligonucleotide developed against the common 3' NCR of influenza A virus genome.Molecular biotechnology · 2013Article
- Chitosans for delivery of nucleic acids.Advanced drug delivery reviews · 2013Review
- Clinical translation of RNAi-based treatments for respiratory diseases.Drug delivery and translational research · 2013Article
- siRNA against the G gene of human metapneumovirus.Virology journal · 2012Article
- Targeting RSV with vaccines and small molecule drugs.Infectious disorders drug targets · 2012Review
- Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection.PloS one · 2012Article
- Mutation of the elongin C binding domain of human respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of NS1 and attenuation of the virus.Virology journal · 2011Article
- The infectious march: the complex interaction between microbes and the immune system in asthma.Immunology and allergy clinics of North America · 2010Review
- Animal models of virus-induced chronic airway disease.Immunology and allergy clinics of North America · 2010Review
- Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells.Cellular immunology · 2010Article
- Secondary RNA structure and its role in RNA interference to silence the respiratory syncytial virus fusion protein gene.Molecular biotechnology · 2009Article
- Nanomedicine for the management of lung and blood diseases.Nanomedicine (London, England) · 2009Review
- Short hairpin RNA targeting NP mRNA inhibiting Newcastle disease virus production and other viral structural mRNA transcription.Virus genes · 2009Article
- RNA interference technologies and therapeutics: from basic research to products.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) causes severe bronchiolitis and is a risk factor for asthma. Since there is no commercially available vaccine against RSV, a short interfering RNA against the RSV-NS1gene (siNS1) was developed and its potential for decreasing RSV infection and infection-associated inflammation in rats was tested.
methodsPlasmids encoding siNS1 or an unrelated siRNA were complexed with a chitosan nanoparticle delivery agent and administered intranasally. Control animals received a plasmid for a non-specific siRNA. After expression of the plasmid in lung cells for 24 hours, the rats were intranasally infected with RSV.
resultsProphylaxis with siNS1 significantly reduced lung RSV titers and airway hyperreactivity to methacholine challenge compared to the control group. Lung sections from siNS1-treated rats showed a sizable reduction in goblet cell hyperplasia and in lung infiltration by inflammatory cells, both characteristics of asthma. Also, bronchoalveolar lavage samples from siNS1-treated animals had fewer eosinophils. Treatment of rats with siNS1 prior to RSV exposure was effective in reducing virus titers in the lung and in preventing the inflammation and airway hyperresponsiveness associated with the infection that has been linked to development of asthma.
conclusionThe use of siNS1 prophylaxis may be an effective method for preventing RSV bronchiolitis and potentially reducing the later development of asthma associated with severe respiratory infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.